medigraphic.com
Colegio de Medicina Interna de México.

2012, Number 4

<< Back Next >>

Med Int Mex 2012; 28 (4)

JC virus disease

López HMA

Language: Spanish
References: 64
Page: 352-359
PDF size: 84.77 Kb.


ABSTRACT

The infection by the JC polyomavirus constitutes a rare diagnosed entity, that happens in the context of severe immunosuppression. There are several clinical scenarios in which the activation and disease by virus JC happens, like the malignancy, the infection by the human immunodeficiency virus, the therapeutic immunosuppression in transplanted patients, and recently in patients treated with monoclonal antibodies like rituximab, efalizumab, and natlizumab used in the therapeutic of Crohn´s disease, multiple sclerosis, generalized erythematous lupus and psoriasis. In this revision are mentioned another forms of presentation of the JC virus infection, beyond the progressive the multifocal leucoencephalopaty in his classic form of presentation, these recently described forms of JC virus infection are the inflammatory reconstitution immune syndrome in patients with infection by HIV with recent beginning of high active antiretroviral therapy, and patients with immunosuppression by drugs, besides other forms of infection by virus JC, as they are the neuronopathy of granular cells, associated to JC virus, meningitis and the encephalitis by virus JC.


REFERENCES

  1. Astrom KE, Mancall EL, Richardson EP Jr (1958) Progressive multifocal leuko-encephalopathy; a unrecognized complication of chronic lymphatic leukaemia and Hodgkin’s disease. Brain 1958;81:93–111.

  2. Padgett, BL, DL Walker, GM ZuRhein, RJ Eckroade, and BH Dessel. Cultivation of papova-like virus from human brain with progressive multifocal leukoencephalopathy. Lancet 1971:1257-1260.

  3. Eng PM, Turnbull BR, Cook SF, Davidson JE, Kurth T, Seeger JD. Characteristics and antecedents of progressive multifocal leukoencephalopathy in an insured population. Neurology 2006;67(5):884–886.

  4. Holman RC, Janssen RS, Buehler JW, Zelasky MT, Hooper WC. Epidemiology of progressive multifocal leukoencephalopathy in the United States: analysis of national mortality and AIDS surveillance data. Neurology 1991;41(11):1733–1736.

  5. Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med 2005;353(4):362–368.

  6. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353(4):375–381.

  7. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353(4):369–374.

  8. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113(20):4834–4840.

  9. Korman BD, Tyler KL, Korman NJ. Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists. Arch Dermatol 2009;145(8):937–942.

  10. Frisque RJ, Bream GL, Cannella MT. Human polyomavirus JC virus genome. J Virol 1984;51:458–469.

  11. Allander T, Andreasson K, Gupta S, Bjerkner A, Bogdanovic G, et al. Identification of a third human polyomavirus. J Virol 2007;81:4130–4136.

  12. Gaynor AM, Nissen MD, Whiley DM, Mackay IM, Lambert SB, et al. Identification of a novel polyomavirus from patients with acute respiratory tract infections. PLoS Pathog 2007;3:e64.

  13. Feng H, Shuda M, Chang Y, Moore PS Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008;319:1096–1100.

  14. Dang X, Bialasiewicz S, Nissen MD, Sloots TP, Koralnik IJ, et al. (2011) Infrequent Detection of KI, WU and MC Polyomaviruses in Immunosuppressed Individuals with or without Progressive Multifocal Leukoencephalopathy. PLoS ONE 6(3):e16736. doi:10.1371/journal.pone.0016736

  15. Nagashima K, Yamaguchi K, Yasui K, Ogiwara H. Progressivemultifocal leukoencephalopathy. Neuropathology andvirus isolation. Acta Pathol Jpn 1981;31:953–961.

  16. Trowbridge PW, Frisque RJ. Identification of three new JC virus proteins generated by alternative splicing of the early viral mRNA. J Neurovirol 1995;1:195–206.

  17. Jensen PN, Major EO. A classification scheme for human polyomavirus JCV variants based on the nucleotide sequence of the noncoding regulatory region. J Neurovirol 2001;7(4):280–287.

  18. Atwood WJ, Amemiya K, Traub R, Harms J, Major EO. Interaction of the human polyomavirus, JCV, with human Blymphocytes. Virology 1992;190(2):716–723.

  19. Monaco MC, Jensen PN, Hou J, Durham LC, Major EO. Detection of JC virus DNA in human tonsil tissue: evidence for site of initial viral infection. J Virol 1998;72(12):9918–9923.

  20. Tan CS, Dezube BJ, Bhargava P, Autissier P, Wuthrich C, Miller J, et al. Detection of JC Virus DNA and Proteins in the Bone Marrow of HIV-Positive and HIV-Negative Patients: Implications for Viral Latency and Neurotropic Transformation. J Infect Dis ;2009.

  21. Monaco MC, Atwood WJ, Gravell M, Tornatore CS, Major EO. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. J Virol 1996;70(10):7004–7012.

  22. Tan CS, Dezube BJ, Bhargava P, Autissier P, Wuthrich C, Miller J, et al. Detection of JC virus DNA and proteins in the bone marrow of HIV-positive and HIV-negative patients: implications for viral latency and neurotropic transformation. J Infect Dis 2009;199(6):881–888.

  23. Randhawa P, Shapiro R, Vats A. Quantitation of DNA of polyomaviruses BK and JC in human kidneys. J Infect Dis 2005;192(3):504–509.

  24. Markowitz RB, Thompson HC, Mueller JF, Cohen JA, Dynan WS. Incidence of BK virus and JC virus viruria in human immunodeficiency virus-infected and uninfected subjects. J Infect Dis 1993;167(1):13–20.

  25. Kitamura T, Aso Y, Kuniyoshi N, Hara K, Yogo Y. High incidence of urinary JC virus excretion in nonimmunosuppressed older patients. J Infect Dis 1990;161(6):1128–1133.

  26. Koralnik IJ, Boden D, Mai VX, Lord CI, Letvin NL. JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy. Neurology 1999;52(2):253–260.

  27. Sabath BF, Major E. Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy. J Infect Dis 2002;186(Suppl 2):S180–S186.

  28. Seth P, Diaz F, Major EO Advances in the biology of JC virus and induction of progressive multifocal leukoencephalopathy. J Neurovirol 2003;9:236–246.

  29. Bofill-Mas S, Clemente-Casares P, Major EO, Curfman B, Girones R Analysis of the excreted JC virus strains and their potential oral transmission. J Neurovirol 2003;9:498–507.

  30. Bofill-Mas S, Formiga-Cruz M, Clemente-Casares P, Calafell F, Girones R. Potential transmission of human polyomaviruses through the gastrointestinal tract after exposure to virions or viral DNA. J Virol 2001;75:10290–10299.

  31. Bofill-Mas S, Girones R. Excretion and transmission of JCV in human populations. J Neurovirol 2001;7:345–349.

  32. Padgett BL, Walker DL. Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy. J Infect Dis 1973;127(4):467–470.

  33. Knowles WA, Pipkin P, Andrews N, Vyse A, Minor P, Brown DW, et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 2003;71(1):115–123.

  34. Weber F, Goldmann C, Kramer M, Kaup FJ, Pickhardt M, Young P, et al. Cellular and humoral immune response in progressive multifocal leukoencephalopathy. Ann Neurol 2001;49(5):636–642.

  35. Giudici B, Vaz B, Bossolasco S, Casari S, Brambilla AM, Luke W, et al. Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response. Clin Infect Dis 2000;30(1):95–99.

  36. Wuthrich C, Kesari S, Kim WK, Williams K, Gelman R, Elmeric D, et al. Characterization of lymphocytic infiltrates in progressive multifocal leukoencephalopathy: co-localization of CD8(+) T cells with JCV-infected glial cells. J Neurovirol 2006;12(2):116–128.

  37. Lima MA, Drislane FW, Koralnik IJ. Seizures and their outcome in progressive multifocal leukoencephalopathy. Neurology 2006;66(2):262–264.

  38. Richardson EP Jr. Progressive multifocal leukoencephalopathy. N Engl J Med 1961;265:815–823.

  39. Garcia-Suarez J, de Miguel D, Krsnik I, Banas H, Arribas I, Burgaleta C. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphopro liferative disorders: impact of novel therapies. Am J Hematol 2005;80:271–281.

  40. Kappos L, Bates D, Hartung HP, et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 2007;6:431–441.

  41. Hartung HP. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol 2009;8:28–31.

  42. Tan K, Roda R, Ostrow L, McArthur J, Nath A. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 2009;72(17):1458–1464.

  43. Du Pasquier RA, Koralnik IJ. Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial? J Neurovirol 2003;9(Suppl 1):25–31.

  44. Vendrely A, Bienvenu B, Gasnault J, Thiebault JB, Salmon D, Gray F. Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy. Acta Neuropathol (Berl) 2005;109(4):449–455.

  45. Huang D, Cossoy M, Li M, Choi D, Taege A, Staugaitis SM, et al. Inflammatory progressive multifocal leukoencephalopathy in human immunodeficiency virus-negative patients. Ann Neurol 2007;62(1):34–39.

  46. Martinez JV, Mazziotti JV, Efron ED, Bonardo P, Jordan R, Sevlever G, et al. Immune reconstitution inflammatory syndrome associated with PML in AIDS: a treatable disorder. Neurology 2006;67(9):1692–1694.

  47. Gray F, Bazille C, Adle-Biassette H, Mikol J, Moulignier A, Scaravilli F. Central nervous system immune reconstitution disease in acquired immunodeficiency syndrome patients receiving highly active antiretroviral treatment. J Neurovirol 2005;11(Suppl 3):16–22.

  48. Tan K, Roda R, Ostrow L, McArthur J, Nath A. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 2009;72(17):1458–1464.

  49. Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med 2005;353(4):362–368.

  50. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353(4):375–381.

  51. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353(4):369–374.

  52. Korman BD, Tyler KL, Korman NJ. Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists. Arch Dermatol 2009;145(8):937–942.

  53. Schwab N, Ulzheimer JC, Fox RJ, et al. Fatal progressive multifocal leukoencephalopathy associated with efalizumab therapy: Insights into the role of leukointegrin aLb2 in JC virus control. Multiple Sclerosis 2009;15:S271–S277.

  54. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113(20):4834–4840.

  55. Mdel, P Martin; Cravens, PD.; Winger, R.; Kieseier, BC.; Cepok, S.; Eagar, TN., et al. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. Arch Neurol 2009;66(8):1016–1020.

  56. Dang X, Koralnik I. A granule cell neuronassociated JC virus variant has a unique deletion in the VP1 gene. Journal of General Virology 2006;87:2533-2537.

  57. Du Pasquier RA, Corey S, Margolin DH, Williams K, Pfister LA, De Girolami U, et al. Productive infection of cerebellar granule cell neurons by JC virus in an HIV+ individual. Neurology 2003;61(6):775–782.

  58. Koralnik IJ, Wuthrich C, Dang X, Rottnek M, Gurtman A, Simpson D, et al. JC virus granule cell neuronopathy: A novel clinical syndrome distinct from progressive multifocal leukoencephalopathy. Ann Neurol 2005;57(4):576–580.

  59. Wuthrich C, Dang X, Westmoreland S, McKay J, Maheshwari A, Anderson MP, et al. Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons. Ann Neurol 2009;65(6):742–748.

  60. Tallantyre EC, Paine SM, Sharp CP, Lowe JS, Gran B. Atypical progressive multifocal leukoencephalopathy associated with an unusual JC polyomavirus mutation. Arch Neurol 2009;66(8):1021–1024.

  61. Moll NM, Rietsch AM, Ransohoff AJ, Cossoy MB, Huang D, Eichler FS, et al. Cortical demyelination in PML and MS: Similarities and differences. Neurology 2007.

  62. Behzad-Behbahani A, Klapper PE, Vallely PJ, Cleator GM, Bonington A. BKV-DNA and JCVDNA in CSF of patients with suspected meningitis or encephalitis. Infection 2003;31(6):374–378.

  63. Viallard JF, Ellie E, Lazaro E, Lafon ME, Pellegrin JL. JC virus meningitis in a patient with systemic lupus erythematosus. Lupus 2005;14(12):964–966.

  64. Blake K, Pillay D, Knowles W, Brown DW, Griffiths PD, Taylor B. JC virus associated meningoencephalitis in an immunocompetent girl. Arch Dis Child 1992;67(7):956–957.




2020     |     www.medigraphic.com